Neurogene
Business Services · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
535 W 24th St Fl 5, New York City, New Y...Phone Number
(877) 237-5020Website
www.neurogene.comRevenue
-Stock Symbol
NGNEIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
2
About Neurogene
Neurogene's mission is to develop life-altering genetic medicines for patients and their families affected by rare, devastating neurological diseases. Our lead programs use adeno-associated virus (AAV) vector-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options currently exist. Neurogene is also developing novel gene therapy technologies to advance treatments for complex neurological diseases that conventional gene therapy cannot successfully address.Explore more
Neurogene Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurogene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Neurogene has new funding data
Click to see if Neurogene had a recent Job posting/layoffs
Earning: See what the market has to say on Neurogene recently announced quarterly report
Product Launch: Get notified when Neurogene launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Neurogene
Check out if Neurogene is spiking on competitors!
Check if Neurogene has recently received funding, and reach out quickly before it becomes old news!
Neurogene, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Neurogene as Masked Content
Find 2 more new buyers
Compare Similar Companies to Neurogene
Compare insights from companies similar to Neurogene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
Neurogene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neurogene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neurogene.
Neurogene financials insights
Gather financial insights about Neurogene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$68.5M
2020
Series B
$115M
2024
Share Placement
$200M
Neurogene Tech Stack
A closer look at the technologies used by Neurogene
Most Recent Scoops
Project
Neurogene has reported that the mean Rett Syndrome Gross Motor Scale (RSGMS) total score increased by 5.2 points when normalized to a one-year rate, a statistically significant improvement on a scale that typically declines by 0.8 points over one year in natural history, with 5 of 7 participants who were previously unable to transition from sitting to standing independently showing improvement post-treatment.
Clinical Operations
Person-Based
Medical Research
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Neurogene News & Media
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D. ...
NEW YORK, April 20, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience building and leading high-performing commercial organizations and launching therapies for raNeurogene Inc. appoints Christy Shafer as Chief Commercial Officer and adds Christine ...
Neurogene Inc. announces Christy Shafer as Chief Commercial Officer and Christine Mikail's addition to its Board of Directors.Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D. ...
NEW YORK--(BUSINESS WIRE)--Apr 20, 2026--Neurogene CMO sells 828 shares to cover taxes | NGNE Insider Trading - Stock Titan
Neurogene CMO Julie Jordan sold 828 shares at $21.89 in a mandatory RSU tax-withholding sale and now reports holding 12,472 shares including future-vesting RSUs.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurogene
Sign Up For FreeTo access detailed company insights
Neurogene's mission is to develop life-altering genetic medicines for patients and their families affected by rare, devastating neurological diseases. Our lead programs use adeno-associated virus (AAV) vector-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. We partner with leading academic researchers, p... Read More
